Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,985,248
  • Shares Outstanding, K 2,028,177
  • Annual Sales, $ 45,006 M
  • Annual Income, $ 8,025 M
  • EBIT $ 2,577 M
  • EBITDA $ 12,337 M
  • 60-Month Beta 0.45
  • Price/Sales 2.61
  • Price/Cash Flow 4.65
  • Price/Book 6.84

Options Overview Details

View History
  • Implied Volatility 22.70% ( -0.46%)
  • Historical Volatility 23.00%
  • IV Percentile 15%
  • IV Rank 17.48%
  • IV High 36.85% on 07/11/24
  • IV Low 19.71% on 12/26/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 7,281
  • Volume Avg (30-Day) 14,336
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 613,449
  • Open Int (30-Day) 693,737

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.47
  • Number of Estimates 10
  • High Estimate 1.61
  • Low Estimate 1.41
  • Prior Year 1.70
  • Growth Rate Est. (year over year) -13.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.04 +3.02%
on 12/13/24
60.09 -5.64%
on 12/03/24
-2.52 (-4.26%)
since 11/29/24
3-Month
51.31 +10.50%
on 10/15/24
61.08 -7.17%
on 11/11/24
+4.96 (+9.59%)
since 09/30/24
52-Week
39.35 +44.09%
on 07/05/24
61.08 -7.17%
on 11/11/24
+5.39 (+10.50%)
since 12/29/23

Most Recent Stories

More News
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment Brightens

Opdivo is reportedly part of PD-1 inhibitors class of drugs, known to aid the immune system's cancer-fighting abilities

VHT : 253.27 (-1.21%)
VOO : 540.52 (-1.20%)
BMY : 56.82 (-1.49%)
Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

SCHD : 27.21 (-0.95%)
BMY : 56.82 (-1.49%)
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.

Dividend stocks have gotten clobbered recently. The main catalyst is the Federal Reserve's recent decision to slow the pace of future interest rate increases. Higher rates tend to weigh on the value of...

BLK : 1,028.91 (-1.46%)
MO : 51.74 (-1.22%)
CSCO : 58.83 (-1.31%)
VZ : 39.51 (-1.03%)
CVX : 143.00 (-0.69%)
UPS : 125.25 (-0.68%)
SCHW : 73.90 (-1.12%)
SCHD : 27.21 (-0.95%)
TXN : 187.82 (-1.76%)
HD : 389.37 (-0.89%)
PFE : 26.40 (-0.83%)
BMY : 56.82 (-1.49%)
Want Decades of Passive Income? 3 Stocks to Buy Right Now

Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills.

ADC : 69.48 (-1.17%)
JPM : 239.49 (-0.70%)
BMY : 56.82 (-1.49%)
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income

If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there...

KO : 62.01 (-0.70%)
ENB : 41.86 (+0.10%)
BMY : 56.82 (-1.49%)
Got $250? 2 Healthcare Stocks to Buy and Hold Forever

One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively...

NVO : 86.38 (-1.13%)
BMY : 56.82 (-1.49%)
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?

It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug development is a frequently laborious and expensive process that can swallow vast...

LLY : 775.16 (-1.02%)
BMY : 56.82 (-1.49%)
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.9300 (-6.42%)
NVS : 97.62 (-0.78%)
ONC.TO : 1.35 (-5.59%)
PFE : 26.40 (-0.83%)
GSK : 33.69 (-1.14%)
BMY : 56.82 (-1.49%)
Stock market today: Wall Street trims its stellar gains as Nvidia's star dims again

U.S. stock indexes trimmed some of their stellar gains for the year

MSTR : 308.31 (-6.57%)
NVDA : 137.41 (+0.29%)
AVGO : 235.12 (-2.74%)
BAC : 43.92 (-0.95%)
$SPX : 5,896.67 (-1.24%)
MS : 125.28 (-1.17%)
JNJ : 143.47 (-1.09%)
$IUXX : 21,146.59 (-1.52%)
PFE : 26.40 (-0.83%)
BMY : 56.82 (-1.49%)
BAX : 28.74 (-1.58%)
$DOWI : 42,527.99 (-1.08%)
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).The regulatory body approved Vabysmo PFS for use in the treatment...

GILD : 92.26 (-1.97%)
REGN : 704.39 (-1.12%)
RHHBY : 34.9480 (-0.35%)
BMY : 56.82 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 59.05
2nd Resistance Point 58.71
1st Resistance Point 58.20
Last Price 56.82
1st Support Level 57.34
2nd Support Level 57.00
3rd Support Level 56.49

See More

52-Week High 61.08
Last Price 56.82
Fibonacci 61.8% 52.78
Fibonacci 50% 50.22
Fibonacci 38.2% 47.65
52-Week Low 39.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar